Equities Analysts Issue Forecasts for Cartesian Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Cartesian Therapeutics in a research note issued to investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($0.47) for the quarter. HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.58) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last released its earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($2.10). Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%. The company had revenue of $8.27 million for the quarter.

RNAC has been the subject of several other reports. Needham & Company LLC started coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 target price for the company. Leerink Partnrs reissued an “outperform” rating on shares of Cartesian Therapeutics in a research note on Tuesday. Finally, SVB Leerink began coverage on Cartesian Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $39.00 target price for the company.

Cartesian Therapeutics Price Performance

RNAC opened at $20.72 on Wednesday. Cartesian Therapeutics has a twelve month low of $11.66 and a twelve month high of $42.60. The business’s 50-day moving average price is $19.29.

Insiders Place Their Bets

In related news, Director Timothy A. Springer acquired 21,612 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was acquired at an average cost of $16.20 per share, for a total transaction of $350,114.40. Following the transaction, the director now directly owns 1,017,228 shares in the company, valued at $16,479,093.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders acquired 22,472 shares of company stock valued at $365,981. 31.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cartesian Therapeutics

A hedge fund recently bought a new stake in Cartesian Therapeutics stock. Hall Laurie J Trustee bought a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned about 0.98% of Cartesian Therapeutics at the end of the most recent reporting period. 86.95% of the stock is owned by hedge funds and other institutional investors.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.